(AOF) – OSE Immunotherapeutics presents the latest positive results from the Phase 1/2 clinical evaluation of its product OSE-279 in advanced solid tumors at the 2024 ESMO Targeted Anticancer Therapies Congress (Esmo TAT) which is being held in Paris from February 26 to 28. “These new results, as well as the additional signal of efficacy with a high rate of anti-tumor response in difficult-to-treat patients, underline the interest of OSE-279 as a potential powerful anti-PD1 treatment”, underlines Silvia Comis, director clinical development.
“This is encouraging for the continuation of its clinical development in pre-identified niche indications, affecting cancers with high medical need,” she continues. “In parallel with its development as a monotherapy, we are exploring a possible evaluation of OSE-279 in combination with other OSE products, including the cancer vaccine, through new patient cohorts.”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
